Sugi Predict

Sugi Predict / Compounds / SCHEMBL3509637

SCHEMBL3509637

SCHEMBL3509637

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](OS(=O)(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP46A1 Q9Y6A2 3/20 1.00
▸ NR1H3 Q13133 3/20 0.83
▸ POLA1 P09884 1/20 0.74
▸ OSBP P22059 3/20 0.71
▸ USP2 O75604 2/20 0.71
▸ RORC P51449 2/20 0.71
▸ LMNA P02545 1/20 0.71
▸ ABCB1 P08183 1/20 0.71
▸ OSBP2 Q969R2 1/20 0.71
▸ GRIN2A Q12879 2/20 0.63
▸ GRIN2D O15399 1/20 0.63
▸ GRIN2B Q13224 1/20 0.63
▸ GRIN2C Q14957 1/20 0.63
▸ GRIN1 Q05586 1/20 0.61
▸ GBA1 P04062 2/20 0.60
▸ UGCG Q16739 2/20 0.60
▸ GBA2 Q9HCG7 2/20 0.60
▸ NPC1L1 Q9UHC9 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161397 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL2304848 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL192029 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL25063545 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL22077526 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL25063542 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL16248291 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL21334348 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL21824301 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL29094045 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12213984-B2 Immunoregulatory agent KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2025-02-04 — — US claimed
US-20240408034-A1 METHOD FOR PREPARING LIPID NANOPARTICLES LEON-NANODRUGS GMBH (DE) 2024-12-12 — — US claimed
EP-4412591-A1 METHOD FOR PREPARING LIPID NANOPARTICLES leon-nanodrugs GmbH (DE) 2024-08-14 — — EP claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 — — CN claimed
WO-2023057596-A1 METHOD FOR PREPARING LIPID NANOPARTICLES LEON-NANODRUGS GMBH (DE) 2023-04-13 — — WO claimed
US-11395826-B2 Immunoregulatory agent KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-07-26 — — US claimed
US-20220054506-A1 IMMUNOREGULATORY AGENT KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-02-24 — — US claimed
US-20180325918-A1 IMMUNOREGULATORY AGENT KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2018-11-15 — — US claimed
EP-3378492-A1 IMMUNOREGULATORY AGENT Kyushu University National University Corporation (JP) 2018-09-26 — — EP claimed
US-20140212949-A1 METHOD FOR PREPARING MICROVESICULAR ADAM15 INDUSTRY ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY (KR) 2014-07-31 — — US claimed
US-6143726-A Complexes of N'-dimethylaminoacetylpartricin A dimethylaminoethylamide, or the salts thereof, and cholesterol 3-sulphate QUATEX N.V. (NL) 2000-11-07 — — US claimed
WO-1998002168-A1 COMPLEXES OF N'-DIMETHYLAMINOACETYLPARTRICIN A DIMETHYLAMINOETHYLAMIDE, OR THE SALTS THEREOF, AND CHOLESTEROL 3-SULPHATE SPA SOCIETÀ PRODOTTI ANTIBIOTICI S.P.A. (IT) 1998-01-22 — — WO claimed
US-5198432-A Cytoprotective agents CENTER FOR INNOVATIVE TECHNOLOGY (US) 1993-03-30 — — US claimed
US-5053406-A COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ROTAVIRAL INFECTIONS GLYCOMED, INC. (US) 1991-10-01 — — US claimed
WO-1991008745-A1 COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ROTAVIRAL INFECTIONS GLYCOMED INCORPORATED (US) 1991-06-27 — — WO claimed
JP-11005742-A — — None — — JP disclosed
EP-4479412-B1 DHEA-DERIVED STEROIDS DEBRECENI EGYETEM (HU) 2025-12-10 — — EP disclosed
US-4822777-A MORE STABLE PARTICLE SIZE, LESS TOXIC LIPOSOME TECHNOLOGY, INC. (US) 1989-04-18 — — US disclosed
EP-0303683-A1 AMPHOTERICIN B/CHOLESTEROL SULFATE COMPOSITION AND METHOD. LIPOSOME TECHNOLOGY INC (US) 1989-02-22 — — EP disclosed
WO-1988006450-A1 AMPHOTERICIN B/CHOLESTEROL SULFATE COMPOSITION AND METHOD LIPOSOME TECHNOLOGY, INC. (US) 1988-09-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180325918-A1 IMMUNOREGULATORY AGENT DOCK2, DOCK5, CDC42 CYP46A1 2140/4885NR1H3 2785/4885POLA1 4367/4885
US-12213984-B2 Immunoregulatory agent DOCK2, DOCK5, CDC42 CYP46A1 2140/4885NR1H3 2785/4885POLA1 4367/4885
US-20220054506-A1 IMMUNOREGULATORY AGENT DOCK2, DOCK5, CDC42 CYP46A1 2140/4885NR1H3 2785/4885POLA1 4367/4885
US-11395826-B2 Immunoregulatory agent DOCK2, DOCK5, CDC42 CYP46A1 2140/4885NR1H3 2785/4885POLA1 4367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.